注射用重组人干扰素α1b联合病毒唑治疗慢性丙型肝炎的临床观察

Clinical study of Recombinant Human Interferon α1b for Injection combined with Ribavirin in the treatment of chronic hepatitis C

目的评价注射用重组人干扰素α1b（赛若金）联合病毒唑治疗慢性丙型病毒性肝炎的临床效果。方法选择66例慢性丙型肝炎患者随机分成联合治疗组与对照组。联合治疗组36例．给予赛若金十扰素60μg，隔日肌肉注射，加上病毒唑450mg，3次／d口服，疗程6个月。对照组30例，单用赛若金干扰素60μg，隔H肌肉注射，疗程6个月。两组停药后随访6个月，分别观察两组慢性丙肝患者治疗前后的临床症状、体征改善状况、生化应答半、病毒应答率和临床副作用。结果疗程结束时联合治疗组临床症状体征的缓解率为88．88％，生化应答牢为88．88％，病毒应答率为69．44％；对照组上述指标分别为83．33％、83．33％、66．66％；经检验两组无显著差异（P〉0．05）。随访6个月联合治疗组的持续应答率为50．00％，而对照组为16．67％，两组有显著差异（P〈0．01）。两组副作用有发热、乏力、胃肠道症状、白细胞下降、肌肉酸痛等，差异无统计学意义（P〉005）。结论赛若金卜扰素联合病毒唑治疗慢性丙型肝炎，促进HCV—RNA的阴转，临床用药安全。

Objective To evaluate the efficacy of Sinogen interferon combined with ribavirin therapy for chronic hepatitis. Methods 66 objects with CHC were randomly divided into combined curative group （n =36, Sinogen and ribavirin） and control group（ n = 30,only Sinogen）, treated for 6 months and followed by an other 6 months. The end of treatment response （ETR） and end of follow- up response （sustained response, SR） were evaluated based on the main symptoms and signs and the serum ALT normalization and seronegative of ttCV - RNA. Results The improvement rate of symptoms and signs（ETR） in combined curative group was 88.88%, the answer rate of live function was 88.88%, the answer rate of virus was 69.44%. The aforementioned data in control group was 83.33% ,83, 33% ,66.66% correspondingly（ P 〉 0.05 ）. But the rate of SR in combined curative group was 50.00%, while the rate was 16. 67% in control group （P 〈 0.01 ）. The side effects in two groups were similar. Conclusion The treatment Sinogen combined with ribavirin was not only safe but also im prove the forward effects.